^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UD TGFbetai NK cells

    i
    Associations
    News

    Trials

    Company:
    The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (NCT06026657)
    Phase 1/2
    Margaret Gatti-Mays
    Recruiting
    Last update posted :
    02/09/2024
    Initiation :
    03/01/2024
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2 • CD4
    |
    HER-2 negative
    |
    gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
    Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (NCT05588453)
    Phase 1/2
    Kari Kendra
    Recruiting
    Last update posted :
    12/29/2022
    Initiation :
    01/01/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    TGFB1
    |
    temozolomide • UD TGFbetai NK cells